Literature DB >> 21315282

Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds.

Jan D Andersson1, M Edward Pierson, Sjoerd J Finnema, Balázs Gulyás, Richard Heys, Charles S Elmore, Lars Farde, Christer Halldin.   

Abstract

INTRODUCTION: The serotonin 1B (5-HT(1B)) receptor has been implicated in several psychiatric disorders and is a potential pharmacological target in the treatment of depression. The aim of this study was to develop a radioligand for positron emission tomography (PET) imaging of the 5-HT(1B) receptor in the primate brain in vivo.
METHODS: Eight carboxamide radioligands (1-8) from three different core structures were radiolabeled with carbon-11 employing N-methylation with [(11)C]methyl triflate on the piperazine structural moiety. In vivo PET evaluation of each radioligand was performed in cynomolgus monkeys and included analysis of radioactive metabolites measured in plasma using high-performance liquid chromatography.
RESULTS: In a total of 12 radiosynthesis of the eight radioligands, the mean decay corrected yield was 11%, and the mean specific radioactivity was 299 GBq/μmol (8075 Ci/mmol) at time of administration. Of the eight tested candidates, [(11)C]6 demonstrated the most promising in vivo characteristics, showing high binding in 5-HT(1B) receptor-rich regions and low binding in the cerebellum. When inspecting data from all eight compounds, lipophilicity appeared as a physicochemical property that could be related to favorable in vivo imaging characteristics.
CONCLUSION: Candidate [(11)C]6, i.e., [(11)C]AZ10419369, exhibited high binding potentials in regions known to contain 5-HT(1B) receptors and was nominated for further preclinical characterization and PET examination in human subjects.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21315282     DOI: 10.1016/j.nucmedbio.2010.08.006

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  10 in total

Review 1.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

2.  Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach.

Authors:  Sjoerd J Finnema; Andrea Varrone; Tzung-Jeng Hwang; Christer Halldin; Lars Farde
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-14       Impact factor: 6.200

Review 3.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 4.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  Synthesis and evaluation of two new candidate high-affinity full agonist PET radioligands for imaging 5-HT1B receptors.

Authors:  Anton Lindberg; Shuiyu Lu; Sangram Nag; Magnus Schou; Jeih-San Liow; Sami S Zoghbi; Michael P Frankland; Robert L Gladding; Cheryl L Morse; Akihiro Takano; Nahid Amini; Charles S Elmore; Yong Sok Lee; Robert B Innis; Christer Halldin; Victor W Pike
Journal:  Nucl Med Biol       Date:  2019-01-26       Impact factor: 2.408

6.  Test-retest reliability of [11C]AZ10419369 binding to 5-HT(1B) receptors in human brain.

Authors:  Magdalena Nord; Sjoerd J Finnema; Martin Schain; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-05       Impact factor: 9.236

7.  ABC transporter-dependent brain uptake of the 5-HT1B receptor radioligand [ (11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig.

Authors:  Miklós Tóth; Jenny Häggkvist; Andrea Varrone; Sjoerd J Finnema; Janine Doorduin; Masaki Tokunaga; Makoto Higuchi; Balázs Gulyás; Christer Halldin
Journal:  EJNMMI Res       Date:  2014-11-30       Impact factor: 3.138

8.  Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.

Authors:  Kai-Chun Yang; Vladimir Stepanov; Stefan Martinsson; Anders Ettrup; Akihiro Takano; Gitte M Knudsen; Christer Halldin; Lars Farde; Sjoerd J Finnema
Journal:  Int J Neuropsychopharmacol       Date:  2017-09-01       Impact factor: 5.176

9.  Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain.

Authors:  Kai-Chun Yang; Akihiro Takano; Christer Halldin; Lars Farde; Sjoerd J Finnema
Journal:  Transl Psychiatry       Date:  2018-07-16       Impact factor: 6.222

10.  Potential for imaging the high-affinity state of the 5-HT1B receptor: a comparison of three PET radioligands with differing intrinsic activity.

Authors:  Anton Lindberg; Ryosuke Arakawa; Tsuyoshi Nogami; Sangram Nag; Magnus Schou; Charles S Elmore; Lars Farde; Victor W Pike; Christer Halldin
Journal:  EJNMMI Res       Date:  2019-11-21       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.